Tacrolimus is a lipid of Polyketides (PK) class. Tacrolimus is associated with abnormalities such as Renal glomerular disease. The involved functions are known as inhibitors, Fungicidal activity, Metabolic Inhibition, Excretory function and Dephosphorylation. Tacrolimus often locates in Hepatic, Mitochondrial matrix and Inner mitochondrial membrane. The associated genes with Tacrolimus are RHOA gene and BGN gene.
To understand associated biological information of tacrolimus, we collected biological information of abnormalities, associated pathways, cellular/molecular locations, biological functions, related genes/proteins, lipids and common seen animal/experimental models with organized paragraphs from literatures.
tacrolimus is suspected in Renal glomerular disease, Candidiasis, Mycoses, PARKINSON DISEASE, LATE-ONSET, Morphologically altered structure, Skin Diseases, Infectious and other diseases in descending order of the highest number of associated sentences.
Disease | Cross reference | Weighted score | Related literature |
---|
We collected disease MeSH terms mapped to the references associated with tacrolimus
There are no associated biomedical information in the current reference collection.
Associated locations are in red color. Not associated locations are in black.
Location | Cross reference | Weighted score | Related literatures |
---|
Function | Cross reference | Weighted score | Related literatures |
---|
Lipid concept | Cross reference | Weighted score | Related literatures |
---|
Gene | Cross reference | Weighted score | Related literatures |
---|
There are no associated biomedical information in the current reference collection.
Authors | Title | Published | Journal | PubMed Link |
---|---|---|---|---|
Charlton M et al. | Everolimus Is Associated With Less Weight Gain Than Tacrolimus 2 Years After Liver Transplantation: Results of a Randomized Multicenter Study. | 2017 | Transplantation | pmid:28817434 |
Cvetkovic M et al. | The deleterious effects of long-term cyclosporine A, cyclosporine G, and FK506 on bone mineral metabolism in vivo. | 1994 | Transplantation | pmid:7513912 |
Singh N et al. | Immunosuppressive-associated leukoencephalopathy in organ transplant recipients. | 2000 | Transplantation | pmid:10708096 |
Zoppo A et al. | Trimetazidine counteracts tacrolimus nephrotoxicity in a hypertensive liver transplant patient. | 1999 | Transplantation | pmid:10551656 |
Tzakis AG et al. | Preliminary experience with campath 1H (C1H) in intestinal and liver transplantation. | 2003 | Transplantation | pmid:12717207 |
Timmermann W et al. | Videomicroscopic imaging of graft mucosa for monitoring immunosuppressive therapy after small intestinal transplantation in rats. | 1999 | Transplantation | pmid:10401762 |
Fabrega AJ et al. | Enhancement of allograft survival by single intraoperative donor-specific blood transfusion combined with FK506. | 1993 | Transplantation | pmid:7506458 |
Jain A et al. | FK506 and pregnancy in liver transplant patients. | 1993 | Transplantation | pmid:7506459 |
Conrotto D et al. | Dramatic increase of tacrolimus plasma concentration during topical treatment for oral graft-versus-host disease. | 2006 | Transplantation | pmid:17060865 |
Khanna A et al. | Tacrolimus induces increased expression of transforming growth factor-beta1 in mammalian lymphoid as well as nonlymphoid cells. | 1999 | Transplantation | pmid:10071036 |
Jiang H et al. | Tacrolimus and cyclosporine differ in their capacity to overcome ongoing allograft rejection as a result of their differential abilities to inhibit interleukin-10 production. | 2002 | Transplantation | pmid:12085006 |
Bechstein WO et al. | Efficacy and safety of tacrolimus compared with cyclosporine microemulsion in primary simultaneous pancreas-kidney transplantation: 1-year results of a large multicenter trial. | 2004 | Transplantation | pmid:15114089 |
Shackleton CR et al. | Lack of correlation between the magnitude of preservation injury and the incidence of acute rejection, need for OKT3, and conversion to FK506 in cyclosporine-treated primary liver allograft recipients. | 1995 | Transplantation | pmid:7570950 |
Jain AB et al. | A prospective randomized trial of tacrolimus and prednisone versus tacrolimus, prednisone, and mycophenolate mofetil in primary adult liver transplant recipients: an interim report. | 1998 | Transplantation | pmid:9846530 |
Qi S et al. | Effect of tacrolimus (FK506) and sirolimus (rapamycin) mono- and combination therapy in prolongation of renal allograft survival in the monkey. | 2000 | Transplantation | pmid:10798741 |
Kovarik JM et al. | Pharmacokinetics of sotrastaurin combined with tacrolimus or mycophenolic acid in de novo kidney transplant recipients. | 2011 | Transplantation | pmid:21157403 |
Xu H et al. | Simultaneous bone marrow and composite tissue transplantation in rats treated with nonmyeloablative conditioning promotes tolerance. | 2013 | Transplantation | pmid:23250336 |
Molmenti EP et al. | Kidney transplantation for end-stage renal failure in liver transplant recipients with hepatitis C viral infection. | 2001 | Transplantation | pmid:11213072 |
Mourer JS et al. | Impact of late calcineurin inhibitor withdrawal on ambulatory blood pressure and carotid intima media thickness in renal transplant recipients. | 2013 | Transplantation | pmid:23715049 |
Maluccio M et al. | Tacrolimus enhances transforming growth factor-beta1 expression and promotes tumor progression. | 2003 | Transplantation | pmid:12923450 |